Bringing together science, technology, and comprehensive solutions to redefine what’s possible in healthcare
ST. PAUL‚ Minn. & OAKLAND, Calif.--(BUSINESS WIRE)-- As the world of healthcare and its dependence on auscultation continues to evolve, digital technology is being introduced to meet the advancing demands of the industry. To meet these changing needs, 3M™ Littmann® Stethoscopes and Eko are announcing a new collaboration that will marry best-in-class 3M Littmann stethoscope technology with advanced Eko digital innovations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201019005547/en/
The new 3M Littmann CORE Digital Stethoscope offers clinicians access to both analog and digital auscultation options and connects to Eko’s software and AI algorithms1 to help clinicians better interpret sounds and detect heart murmurs. Benefits to clinicians include:
- Helps increase confidence in auscultation assessments
- Amplification2 and active noise cancellation
- Visualization of sound data during auscultation
- Access to Eko’s AI and clinical decision support, helping providers to screen for heart murmurs during routine physical exams
- Access to Eko’s telemedicine software, making these benefits available for both in-person and remote patient care
“Today, 3M Littmann Stethoscopes embarks upon a new era in our long history as a pioneer in auscultation innovation and quality by introducing our most advanced stethoscope yet,” said Kristi Barnett, Sr. Director, 3M Medical Devices. “The new 3M Littmann CORE Digital Stethoscope combines the superior acoustics of the Littmann Cardiology IV Stethoscope with Eko's digital technology and software to aid and enhance a clinician’s auscultation assessments.”
The collaboration between 3M Littmann Stethoscopes and Eko brings together two innovative companies that are focused on delivering comprehensive health care solutions that drive better patient outcomes.
“This combination is a gamechanger – allowing a physician in rural America or a nurse treating patients in a non-office setting to have access to cutting-edge clinical decision support.”
In January of this year, Eko received FDA clearance for an algorithm that can detect the presence of suspected heart murmurs. The 3M Littmann CORE Digital Stethoscope can connect to Eko software, including its heart murmur AI1 and its telemedicine software, enabling enhanced in-person or remote patient care.
“For clinicians, listening is a gateway to making critical diagnoses. Being able to confidently assess heart and lung sounds helps ensure the best cardiac and pulmonary care possible,” said Connor Landgraf, co-founder and CEO, Eko. “Partnering with 3M Littmann Stethoscopes allows us to incorporate the power of our digital and machine learning technology alongside the stethoscope trusted by millions of clinicians worldwide, which can help impact patient outcomes and quality of care. Combining the 3M Littmann CORE Digital Stethoscope with the Eko platform of software and AI helps clinicians elevate cardiopulmonary care to a whole new level.”
1Subscription required. Eko Analysis Software is currently available only in the U.S. Learn more at ekohealth.com/platform
2Up to 40x amplification based on comparison of analog versus electronically assisted amplified listening with maximum volume at the peak frequency (125 Hz).
About 3M™ Littmann® Stethoscopes
3M™ Littmann® Stethoscopes is a global leader in auscultation technology - providing innovative solutions to improve patient care. Littmann stethoscopes are trusted worldwide for precision, acoustic excellence, reliable design and exceptional performance, helping clinicians detect difficult-to-hear body sounds and improve patient outcomes.
At 3M, we apply science in collaborative ways that improve lives daily. With $32 billion in sales, our 96,000 employees connect with customers all around the world. Learn more about 3M’s creative solutions to the world’s problems at www.3M.com or on Twitter @3M or @3MNews.
Eko is elevating the way clinicians detect and monitor cardiac and respiratory disease by bringing together advanced sensors, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by tens of thousands of clinicians treating millions of patients around the world, in-person, and through telehealth. The company is headquartered in Oakland, California and privately held, with investments from ARTIS Ventures, NTT Venture Capital, DigiTx Ventures, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.